Document is current
Any future updates will be listed below
-
Authors
Carpentier, Alexandre https://orcid.org/0000-0001-7312-6358
Stupp, Roger https://orcid.org/0000-0002-5483-3118
Sonabend, Adam M. https://orcid.org/0000-0002-8347-1945
Dufour, Henry
Chinot, Olivier https://orcid.org/0000-0001-6317-9691
Mathon, Bertrand https://orcid.org/0000-0002-9182-5846
Ducray, François
Guyotat, Jacques
Baize, Nathalie
Menei, Philippe
de Groot, John
Weinberg, Jeffrey S. https://orcid.org/0000-0001-5587-6673
Liu, Benjamin P. https://orcid.org/0000-0003-0122-3866
Guemas, Eric
Desseaux, Carole
Schmitt, Charlotte
Bouchoux, Guillaume
Canney, Michael
Idbaih, Ahmed
- License Information
-
More Information
Article History
Received: 23 February 2023
Accepted: 6 February 2024
First Online: 23 February 2024
Competing interests
: AMS and RS have received in-kind (drug) support from Bristol-Myers Squibb, in-kind (ultrasound devices) and research support from Carthera, and in-kind (drug) and research support from Agenus. AMS and RS are co-authors of intellectual property filed by Northwestern University related to therapeutic ultrasound. RS has acted or is acting as a scientific advisor or has served on advisory boards for the following companies: Alpheus Medical, AstraZeneca, Boston Scientific, Carthera, Celularity, GT Medical, Insightec, Lockwood (BlackDiamond), Northwest Biotherapeutics, Novocure, Syneos Health (Boston Biomedical), TriAct Therapeutics, and Varian Medical Systems. AMS is a consultant for Carthera and Enclear Therapeutics. MC, CD, CS, GB, and AC are employees of Carthera, inventors of patents related to the technology, or have stock ownership in Carthera. AC has received funding support from Horizon 2020 European Innovation Council; is a paid consultant of Carthera; and is part of the Board of Directors of Carthera. FD is acting as a scientific advisor or has served on advisory boards for the following companies: Novocure, Servier. AI has received research grants from Carthera, Transgene, Sanofi, Nutritheragene; travel funding from Enterome and Carthera; personal fees for advisory board from Leo Pharma, Novocure, Novartis, and Boehringer Ingelheim outside the submitted work. The remaining authors declare no competing interests.
